Table 2.
Resource use, costs, and QALY for screening 500,122 candidates over five years.
| Outcomes | PGT | XGT | Incremental |
|---|---|---|---|
| Cancers treated | 106 | 98 | −8 |
| CIN2/3 treated | 3993 | 3701 | −292 |
| CIN2+ treated | 4099 | 3799 | −300 |
| Colposcopies conducted | 36,809 | 29,679 | −7130 |
| HPV tests conducted | 540,799 | 543,245 | 2446 |
| Cytology conducted | 86,419 | 80,392 | −6027 |
| Clinic consultations | 601,796 | 592,009 | −9787 |
| Cost of HPV tests | SGD 62,106,581 (USD 73,848,491) |
SGD 71,753,834 (USD 85,319,660) |
SGD 9,647,253 (USD 11,471,169) |
| Cost of cytology | SGD 5,953,061 (USD 7,078,551) |
SGD 5,658,456 (USD 6,728,247) |
−SGD 294,605 (−USD 350,303) |
| Cost of colposcopy | SGD 14,259,917 (USD 16,955,906) |
SGD 11,486,606 (USD 13,658,271) |
−SGD 2,773,311 (−USD 3,297,635) |
| Cost of clinic consultation | SGD 45,038,254 (USD 53,553,215) |
SGD 44,310,726 (USD 52,688,140) |
−SGD 727,528 (−USD 865,075) |
| Total cost | SGD 145,904,751 (USD 173,489,597) |
SGD 150,396,871 (USD 178,831,000) |
SGD 4,492,120 (USD 5,341,403) |
| Total QALY loss | −6528.3 | −6253.88 | 274.42 |
| ICER | - | - | SGD 16,370/QALY (USD 19,465/QALY) |
Abbreviations: CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus; ICER: incremental cost-effectiveness ratio; PGT: HPV partial genotyping; QALY: quality-adjusted life years; XGT: HPV extended genotyping.